by Bob Kronemyer
Share

SetPoint Medical’s Chief Medical Officer, Dr. David Chernoff, discusses the positive, long-term 24-month results from their study, which support the ongoing clinical development of a novel bioelectronic device for the treatment of Rheumatoid Arthritis.

The article includes a video of Dr. David Chernoff discussing the data at the NANS Summer Series Meeting.